Mahmut Gümüş
Medeniyet Üniversitesi Göztepe Eğitim ve Araştırma Hastanesi · 334 works · 18,682 citations · h-index 38
Top works
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
- Hepatogastroenterology
- Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
- Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
- Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
- The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment
- First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
- Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).
- The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer.
- Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
- Prognostic Significance of Perineural Invasion in Patients with Gastric Cancer Who Underwent Curative Resection
- Results after multivisceral resections of locally advanced colorectal cancers: an analysis on clinical and pathological t4 tumors